Insilico Medicine, a biotechnology company utilizing generative artificial intelligence, has launched its Nach01 foundation model on Amazon Web Services (AWS). This model is now accessible via the AWS Marketplace, which assists companies in finding and deploying solutions from AWS partners. The launch is part of a collaboration between AWS and Insilico Medicine’s Pharma.AI Platform to provide advanced AI tools for drug design.
Nach01 employs a large language model capable of processing structural and spatial data. It integrates features from its predecessors to solve various tasks, offering extensive chemical knowledge. Trained using Amazon SageMaker, AWS’s machine learning service, Nach01 allows scientists to develop and apply large-scale generative models for retrosynthesis and molecular prediction.
The demand for Nach01 was notable even before its official release. Now available through AWS Marketplace, it offers streamlined access for researchers and pharmaceutical companies of all sizes.
Alex Zhavoronkov, Founder and CEO of Insilico Medicine, stated, “Natural and chemical languages+point cloud transformer (NACH01-PC) is one of the most capable multimodal foundational models in our arsenal and in the industry with the potential to produce novel medicines and save lives.”
Jon Jones, VP and Global Head of Startups at AWS, added, “Making frontier biochemistry models like NACH01-PC broadly available to the research community around the world…is one of the many ways AWS sees generative AI making a positive impact in people’s lives.”
Key features of Nach01 include compatibility with Python code or API calls, 2D and 3D predictive models, inference and fine-tuning capabilities. The model can be deployed via Amazon SageMaker with secure access through AWS Marketplace.
Organizations interested in accessing Nach01 can request it directly from its listing on the AWS Marketplace or contact Insilico Medicine for support.
Insilico Medicine focuses on integrating biology, chemistry, medicine, and science research through next-generation AI systems. The company aims to discover innovative drugs for various diseases using deep generative models and other machine learning techniques.
